<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358019</url>
  </required_header>
  <id_info>
    <org_study_id>2523355-001</org_study_id>
    <nct_id>NCT01358019</nct_id>
  </id_info>
  <brief_title>A Study of LY2523355 in Patients With Solid Cancer</brief_title>
  <acronym>2523355-001</acronym>
  <official_title>A Phase 1 Study of LY2523355 in Patients With Solid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine a recommended dose for subsequent phase
      trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients
      with advanced and/or metastatic cancer. The secondary objectives are to study the
      pharmacokinetics and antitumor effect.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity based on the Common Terminology Criteria for Adverse Events v4.0</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <description>Plasma concentration of LY2523355 and metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor effect</measure>
    <description>Response evaluation criteria in solid tumors</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>LY2523355</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2523355</intervention_name>
    <description>Days 1, 2, and 3 in a cycle that consists of 21-days</description>
    <arm_group_label>LY2523355</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological and/or cytological evidence of solid tumors

          -  A diagnosis of advanced and/or metastatic solid tumors

          -  Patients who are refractory to standard therapy or for which no proven effective
             therapy exists

          -  Written informed consent

          -  Appropriate bone marrow, hepatic and renal functions

          -  ECOG PS =&lt; 1

        Exclusion Criteria:

          -  Have serious preexisting complication

          -  Have active infection which requires intravenous antibiotics

          -  Have symptomatic central nervous system metastases

          -  Have current acute or chronic leukemia

          -  Have had an autologous or allogenic hematopoietic stem cell transplantation

          -  Have active multiple cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Manager</last_name>
    <role>Study Director</role>
    <affiliation>Kyowa Hakko Kirin Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

